Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M9VE
|
||||
| Former ID |
DIB001574
|
||||
| Drug Name |
EXISULIND
|
||||
| Synonyms |
Aposulind; Aptosyn; Sulindac sulfone; FGN-1; Prevatac (former Brand Name); Exisulind < Prop INN >; (Z)-5-Fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-indene-3-acetic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Colorectal cancer [ICD9: 153, 154; ICD10:C18-C21] | Phase 3 | [1] | ||
| Company |
OSI Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H17FO4S
|
||||
| Canonical SMILES |
CC1=C(CC(=O)O)c2cc(F)ccc2/C/1=C\\c3ccc(cc3)S(=O)(=O)C
|
||||
| InChI |
1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
|
||||
| InChIKey |
MVGSNCBCUWPVDA-MFOYZWKCSA-N
|
||||
| CAS Number |
CAS 59973-80-7
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | CGMP-specific 3',5'-cyclic phosphodiesterase | Target Info | Modulator | [2] | |
| KEGG Pathway | Purine metabolism | ||||
| cGMP-PKG signaling pathway | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | cGMP effects | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00085826) A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients. U.S. National Institutes of Health. | ||||
| REF 2 | Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.